NCT05564390 2026-04-20
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06484062 2026-04-13
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06661915 2026-04-13
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06327685 2026-04-01
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting
NCT04953897 2026-03-10
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Recruiting
NCT04953910 2026-03-10
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Recruiting
NCT07148947 2026-03-04
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT05010122 2026-02-18
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting